Long ago Diabetic Investor noted that the Sanofi strategy had many possibilities but the key was the ability to execute. Back then, we thought Sanofi was on the right track and while the strategy was ambitious they had the resources necessary to see it through to the end. Sadly the company has failed to execute and frankly is no closer to overtaking Novo then Lilly is. Novo may not be the company it once was and they do have their own set of issues but they have never strayed from their core competencies. Put another way, they know who they are and what they are good at.